Advertisement
Screener

INTENSITY THERAPEUTICS, INC. (INTS) ROE

INTENSITY THERAPEUTICS, INC. ROE

Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • INTENSITY THERAPEUTICS, INC. roe for the quarter ending 2026-06-30 was -121.15%, a change of 454.76% year-over-year.
  • INTENSITY THERAPEUTICS, INC. roe for the quarter ending 2026-03-31 was -107.16%, a change of 4387.46% year-over-year.
  • INTENSITY THERAPEUTICS, INC. roe for the quarter ending 2025-12-31 was -97.73%, a change of 459.78% year-over-year.
  • INTENSITY THERAPEUTICS, INC. roe for the quarter ending 2025-09-30 was -162.50%, a change of 422.56% year-over-year.
  • INTENSITY THERAPEUTICS, INC. roe for fiscal 2025 was -97.73%, a change of 459.78% from fiscal 2024.
  • INTENSITY THERAPEUTICS, INC. roe for fiscal 2024 was -557.51%, a change of -477.44% from fiscal 2023.
  • INTENSITY THERAPEUTICS, INC. roe for fiscal 2023 was -80.06%, a 259.43% decline from fiscal 2022.
  • INTENSITY THERAPEUTICS, INC. roe for fiscal 2022 was 50.22%.
Available history
2022-12-31 to 2026-06-30
Data captured

Historical ROE

DateROENet income 12 monthNet income 3 monthShareholder equity
2026-06-30-121.15%-$11.16M-$3.01M$9.21M
2026-03-31-107.16%-$10.69M-$2.43M$9.98M
2025-12-31-97.73%-$11.61M-$3.05M$11.88M
2025-09-30-162.50%-$11.74M-$2.67M$7.22M
2025-06-30-575.92%-$12.58M-$2.54M$2.18M
2025-03-31-4494.61%-$15.01M-$3.35M$334,000.00
2024-12-31-557.51%-$16.27M-$3.18M$2.92M
2024-09-30-585.07%-$16.26M-$3.51M$2.78M
2024-06-30-282.04%-$15.08M-$4.97M$5.35M
2024-03-31-142.00%-$13.81M-$4.60M$9.72M
2023-12-31-80.06%-$10.54M-$3.17M$13.16M
2023-09-30-55.79%-$8.88M-$2.33M$15.91M
2023-06-30-54.99%-$8.32M-$3.70M$15.13M
2023-03-3141.03%-$6.55M-$1.34M-$15.96M

Annual ROE

DateROENet income 12 monthShareholder equity
2025-12-31-97.73%-$11.61M$11.88M
2024-12-31-557.51%-$16.27M$2.92M
2023-12-31-80.06%-$10.54M$13.16M
2022-12-3150.22%-$7.58M-$15.1M

Similar stocks

Stock NameCountryMarket CapPE Ratio
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
Pluri Inc. (PLUR)$0.014B
IN8BIO, INC. (INAB)United States$0.012B-0.76
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Passage BIO, Inc. (PASG)United States$0.015B-0.43
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
BioCardia, Inc. (BCDA)United States$0.016B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
Jasper Therapeutics, Inc. (JSPR)United States$0.020B-0.37